Effects of combined treatment of alendronate of sodium, calcic atorvastatin and ipriflavone in osteoporosis induced with dexamethasone in female rats;Efeitos de tratamento combinado de alendronato de sódio, atorvastatina cálcica e ipriflavona na osteoporose induzida com dexametasona em ratas

Revista Brasileira de Ciencias Farmaceuticas/Brazilian Journal of Pharmaceutical Sciences

Volumn 42, Issue 1, 2006, Pages 99-107

  Pinto, Aloísio Da Silva ^a   De Oliveira, Tânia Toledo ^a   Del Carlo, Ricardo Junqueira ^a   Nagem, Tanus Jorge ^a,b   Fonseca, Cláudio César ^a   De Moraes, George Henrique Kling ^a   Ferreira Jr , Davilson Bragine ^a   Cardoso, Carlos Antonio ^a  

^a FEDERAL UNIVERSITY OF VIÇOSA   (Brazil)

^b FEDERAL UNIVERSITY OF OURO PRETO   (Brazil)

Author keywords

Alendronate; Atorvastatin; Dexamethasone; Drug combinations; Ipriflavone; Osteoporosis

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE BONE ISOENZYME; ATORVASTATIN; BIOLOGICAL MARKER; CALCIUM; CITALOR; DEXAMETHASONE; IPRIFLAVONE; PHOSPHORUS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE DENSITY; BONE REMODELING; CALCIUM BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFECT; MORPHOMETRICS; NONHUMAN; OSTEOPOROSIS; PHOSPHATE BLOOD LEVEL; RAT; TRABECULAR BONE;

EID: 33745909147     PISSN: 15169332     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. ALBANESE, C.B.; CUDD, A.; ARGENTINO, L.; ZAMBONIN-ZALLONE, A.; MACINTYRE, I. Ipriflavone directly inhibits osteoclastics activity. Biochem Biophys Res Commun, v. 199, p. 930-936, 1994.
2. ARJMANDI, B.H.; BIRNBAUM, R.S.; JUMA, S.; BARENGOLTS, E.; KUKREJA, S.C. The synthetic phytoestrogen, ipriflavone, and estrogen prevents bone loss by different mechanisms. Calcif. Tissue Int, v. 66, p. 61-65, 2000.
3. AU, W. Y. Cortisol stimulation of parathyreoid hormone secretion by rat parathyroid glands in organ culture. Science, v. 193, n. 4257, p. 1015-1017, 1976.
4. AZRIA, M.; BEHHAR, C.; COOPER, S.; LAC, K. Effect of ipriflavone on osteoclasts motily and resorption in vitro in vivo studies. Calcif. Tissue Int., v. 52, p. 16-20, 1993.
5. BENFORD, H.L.; MCGOWAN, N.W.A.; HELFRICH, M.H.; NUTALL, M.E.; ROGER, M.J. Visualization of bisphosphonate-induced caspase-3-activity in apoptotic osteoclasts in vitro. Bone, v. 28, n. 5, p. 465-473, 2001.
6. BIKLE, D.D. Biochemical markers in the assessment of bone disease. Am. J. Med., v. 103, p. 427-436, 1997.
7. BLACK, D.M.; GREESPAN, S.L.; ENSRUD, K.E.; PALERMO, L.; MCGOWAN, J.A. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N. Engl. J. Med., v. 349, p. 1207-1215, 2003.
8. BONE, H.G.; GREESPAN, S.L.; McKEEVER, C.; BELL, N.; DAVIDSON, M.; DOWNS, R. W. Alendronate and estrogen effects in postmenopausal women with low bone mineral density. J. Clin. Endocrinol. Metab., v. 85, p. 720-726, 2000.
9. CECCHETTIN, M.; BELLOMETTI, S.; CREMONESI, G.; SOLIMENO, L.P.; TORRI, G. Metabolic and bone effects after administration of ipriflavone and salmon calcitonin in postmenopausal osteoporosis. Biomed. Pharmacother., v. 49, p. 465-468, 1995.
10. CHENG, S.L.; ZHANG, S.F.; NELSON, T.L.; WARLOW, P.M.; CIVITELLI, R. Stimulatory of human osteoblasts differentiation and function by ipriflavone and its metabolites. Calcif. Tissue Int., v. 55, p. 356-362, 1994.
11. CORTET, B. Combination therapy for osteoporosis. J. B. Spin., v. 71, p. 363-364, 2004.
12. COSMAN, F.; NIEVES, J.; WOELFERT, L.; FORMICA, C., GORDON, S., SHEN, V. Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal. J. Bone. Miner. Res., v. 16, p. 925-931, 2001.
13. FLEISCH, H.; RUSSEL, R.G.G.; BISAZ, S.; MUHLBAUER, R.C.; WILLIAMS, D.A. The inhibitory effect of diphosphonates on the formation of calcium phosphate crystal in vitro and on aortic and kidney calcification in vivo. Eur. J. Clin. Invest., v. 1, p. 12-18, 1970.
14. GAMBACCIANY, M.; SPINETTI, A.; PIAGGESI, L.; CAPPAGLI, B.; TAPONECO, F.; MANETTI, P.; WEISS, C.; TETEI, G.C.; LA COMMARE, P.; FACCHINI, V. Ipriflavone prevents the bone loss mass reduction in premenopausal women treated with gonadotropin hormone-releasing hormone agonists. Bone Liner, v. 26, p. 19-26, 1994.
15. GUYTON, A.C.; HALL, J.E. Tratado de fisiologia médica. 10. ed. Rio de Janeiro: Guanabara Koogan, 2002. 973 p.
16. HARRIS, S. T.; ERIKSEN, E. F.; DAVIDSON, M.; ETTINGER, M. P.; MOFFETT, A. H.; BAYLINK, D. J. Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women. J. Clin. Endocrinol. Metab., v. 86, p. 1890-1897, 2001.
17. HOLME, D.J.; PECK, H. Analytical biochemistry. Singapore, Longman Singapore Publishers, 1998. 488 p.
18. JUNQUEIRA, L.C.U.; CARNEIRO, J.; KELLEY, R.O. Basic histology. 5.ed. Philadelphia: Prentice-Hall International Inc., 1986. 518 p.
19. KATAI, Y.; KAWASE, T.; NAKANO, T.; MIKUNI-TABAGAKI, Y.; SAITO, S. Effects of iprivaflone and estrogen on the differentiation and proliferation of osteogenic cells. Calcif. Tissue Int., v. 51, p. 11-15, 1992.
20. 2+, P and ALP activity in osteoporosis-inducedrats. J. Vet. Sci., v. 4, n. 2, p. 151-154, 2003.
21. LINDSAY R. Prevention and treatment of osteoporosis. Lancet, v. 341, p. 801-805, 1993.
22. LINDSAY, R.; COSMAN, F.; LOBO, R.A.; WALSH, B.W.; HARRIS, S.T.; REAGAN, J.E. Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: a randomized, controlled clinical trial. J. Clin. Endocrinol. Metab., v. 84, p. 3076-3081, 1999.
23. LUCKMAN, S.P.; HUGHES, D.E.; COXON, F.P.; GRAHAM, R.; RUSSELL, G.; ROGERS, M.J. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J. Bone Miner. Res., v. 13, p. 581-589, 1998.
24. MEYER, J.L.; NANCOLLAS, G.H. The influence of multidentate organic phophonates on the crystal growth of hydroxiapatite. Calcif. Tissue Res., v. 13, p. 295-303, 1973.
25. MOTTA, V.T. Bioquímica clínica para laboratório: princípios e interpretações. 4.ed. Porto Alegre: Editora Médica Missau, 2003. 419 p.
26. MUNDY, G.R. Statins and their potential for osteoporosis. Bone, v. 29, n. 6, p. 495-497, 2001.
27. NOTOYA, K.; YOSHIDA, K.; TAKETOMI, S.; YAMAZAKI, I.; KUMEGAWA, M. Inhibitory effects of ipriflavone on osteoclast-mediated bone resorption and new osteoclast-mediated formation in long-term cultures of mouse unfractionated bone cells. Calcif. Tissue Int., v. 53, p. 206-209, 1993.
28. PASSERI, M.; BIONDI, D.; DALL'AGLIO, E.; PEDRAZONI, M.; BUFALINO, L.; CASTIGLIONE, G.N.; DI PEPPE, C.; ABATE, G. Effects of 2-year therapy with ipriflavone in elderly women with established osteoporosis. Ital. J. Min. Electrolyte. Metab., v. 9, p. 137-144, 1995.
29. PATSCHAN, D.; LODDENKEMPER, K.; BUTTGEREIT, F. Molecular mechanisms of glucocorticoid-induced osteoporosis. Bone, v. 29, n. 6, p. 498-505, 2001.
30. PETERSON, J.; DWYER, J. Flavonoids: Dietary occurrence and biochemical activity. Nut. Res., v. 18, n. 12, p. 1995-2018, 1998.
31. REID, I.R. Glucocorticoid osteoporosis-mechanisms and management. Eur. J. Endocrinol., v. 137, n. 3, p. 209-217, 1997.
32. REID, I.R.; IBBERTSON, H.K. Evidence for decreased tubular reabsorption of calcium in glucocorticoid-treated asthmatics. Horm. Res., v. 21, n. 4, p. 200-204, 1987.
33. SAHNI, M.; GUENTHER, H.L.; FLEISCH, H.; MARTIN, T.J. Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. J. Clin. Invest., v. 91, p. 2004-2011, 1993.
34. SANTOS, P. S. Desenvolvimento de um modelo experimental para o estudo da osteoporose. 2004. 50 f. Dissertação (Mestrado em Medicina Veterinária) - Departamento de Veterinária, Universidade Federal de Viçosa, Viçosa, 2004.
35. SARAIVA, G.L.; LAZARETTI-CASTRO, M. Marcadores bioquímicos da remodelação óssea na prática clínica. Arq. Bras. Endocrinol. Metab., v. 46, n. 1, p. 72-78, 2002.
36. SUGIMOTO, T.; BROWN, A.J.; RITTER, C., MORRISSEY, J.; SLATOPOLSKY, E.; MARTIN, K.J. Combined effects of dexamethasone and 1,25-dihydroxyvitamin D3 on parathyroid hormone secretion in cultured bovine parathyroid cells. Endocrinology, v. 125, n. 2, p. 638-641, 1989.
37. THORNDIKE, E.A.; TURNER, A. In search of an animal model for postmenopausal diseases. Front. Biosci., Tampa, v. 3, p. 17-26, 1998.
38. VIEIRA, J.G. Considerações sobre os marcadores bioquímicos do metabolismo ósseo e sua utilidade prática. Arq. Bras. Endocrinol. Metab., v. 43, p. 415-422, 1999.
39. YAMAMOTO, A.; YAMAMURA, T.; YOKOYAMA, S.; SUDO, H.; MATSUZAWA, Y. Combined drug therapy - cholestyramine and compactine - for familial hipercolesterolemia. J. Clin. Pharmacol. Ther. Toxicol., v. 22, p. 493-497, 1984.
40. YAMAZAKI, I. Effect of ipriflavone on the response of uterus and thyroid to estrogen. Life Sci., v. 38, p. 757-764, 1986.